MenoCHECK | Rapid Home Screening Test

The typical “mature woman” is aged 40 years or older and has completed childbearing. During their late 40’s, most women enter the menopausal transition. This period of physiological change is due to ovarian senescence (the process of deterioration with age) and estrogen decline and is usually completed between ages 51 and 56. Menopause marks a defining point in this transition. Specifically, menopause is defined by the World Health Organization as the point in time of permanent menstruation cessation due to loss of ovarian function. Clinically, the menopause refers to a point in time that follows 1 year after menstruation cessation. The time leading up to menopause is called perimenopause. With ovarian senescence, declining hormone levels have specific effects on many tissues. Some effects lead to physical complaints, such as vasomotor symptoms (night sweats, hot flashes, and flushes) and vaginal dryness, whereas others are metabolic and structural changes. These include osteopenia, osteoporosis, skin thinning, fatty replacement of the breast, cardiovascular changes, and genitourinary atrophy. As a result, postmenopausal women have specific issues associated with ageing and estrogen loss that may negatively affect their individual health  

Mature women (around age 40) showing signs of menopause:

• irregular menstruation, which finally stops completely
• hot flashes
• hair loss
• sleep disorders
• vaginal dryness

• MenoQUICK detects the level of FSH to prove whether or not a woman has entered perimenopause (the time when the ovaries gradually begin to make less estrogen). If a woman knows that she has already entered perimenopause, she has the possibility to take the necessary steps to keep her body healthy and to avoid risks involved in menopause (e.g. osteoporosis, rising blood pressure, high cholesterol).
• Safe & easy test procedure at home with immediate results.
• Narrows down the possible cause of symptoms. A doctor or gynecologist can use these results to discuss hormone treatment to evaluate the risk of osteoporosis.

Urine

5 mins

FSH (Follicle Stimulating Hormone)

>99.9%

The self-tests are manufactured by NanoRepro AG, an ISO 9001, ISO 13485 and EC certified German company.